What is STERIS's cash & equivalents?

STERIS (STE) reported cash & equivalents of $439.6M in Q1 2026.

How has STERIS's cash & equivalents changed year-over-year?

STERIS's cash & equivalents increased by 156.0% year-over-year, from $171.7M to $439.6M.

What is the long-term trend for STERIS's cash & equivalents?

Over 5 years (2021 to 2026), STERIS's cash & equivalents has grown at a 14.8% compound annual growth rate (CAGR), from $220.53M to $439.6M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

STERIS STE Cash & Equivalents

Cash & Equivalents at other companies

Baxter InternationalBAX

$2.02B-12.1%

EcolabECL

$519.8M-55.3%

3MMMM

$3.73B-41.1%

StrykerSYK

$2.88B+24.1%

Mesa LaboratoriesMLAB

$26.93M-1.4%

Boston ScientificBSX

$850M+146%

Other financials

Income statement

See full

Revenue$1.6B+7.3%

Gross profit$697.2M+8.8%

Operating income$316.8M+46.6%

Net income$220.2M+51.2%

EPS (diluted)$2.24+52.4%

Balance sheet

See full

Total debt$2.1B-10.3%

Total equity$7.2B+8.8%

Total assets$10.7B+5.8%

Cash flow

See full

Operating cash flow$335.4M+28.6%

CapEx$90.2M+27.2%

Free cash flow$245.2M+29.1%

Valuation

See full

Market cap$20.52B-9.4%

Enterprise value$22.17B-8.8%

P/E26.2×-8.8×

P/S3.5×-0.6×

Profitability

See full

Gross margin44.2%+0.2pp

Operating margin18.6%+2.7pp

Net margin13.2%+1.9pp

FCF margin16.4%+2.1pp

Returns & leverage

See full

Return on equity11.3%+1.8pp

Debt / equity0.3×-0.1×

Current ratio2.1×+0.1×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: STERIS’s 10-K, filed May 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about STERIS's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is STERIS's cash & equivalents?: STERIS (STE) reported cash & equivalents of $439.6M in Q1 2026.
How has STERIS's cash & equivalents changed year-over-year?: STERIS's cash & equivalents increased by 156.0% year-over-year, from $171.7M to $439.6M.
What is the long-term trend for STERIS's cash & equivalents?: Over 5 years (2021 to 2026), STERIS's cash & equivalents has grown at a 14.8% compound annual growth rate (CAGR), from $220.53M to $439.6M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.